Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Intraoperative Adductor Canal Block for Augmentation of Periarticular Injection in Total Knee Arthroplasty: A Cadaveric Study.

Pepper AM, North TW, Sunderland AM, Davis JJ.

J Arthroplasty. 2016 Sep;31(9):2072-6. doi: 10.1016/j.arth.2016.02.030. Epub 2016 Feb 26.

PMID:
26996675
2.

Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

North TW, Villalobos A, Hurwitz SJ, Deere JD, Higgins J, Chatterjee P, Tao S, Kauffman RC, Luciw PA, Kohler JJ, Schinazi RF.

Antimicrob Agents Chemother. 2014 Jul;58(7):3927-33. doi: 10.1128/AAC.02522-14. Epub 2014 Apr 28.

3.

Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART.

Deere JD, Kauffman RC, Cannavo E, Higgins J, Villalobos A, Adamson L, Schinazi RF, Luciw PA, North TW.

PLoS One. 2014 Feb 5;9(2):e87914. doi: 10.1371/journal.pone.0087914. eCollection 2014.

4.

Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.

Wadford DA, Kauffman RC, Deere JD, Aoki ST, Stanton RA, Higgins J, Van Rompay KK, Villalobos A, Nettles JH, Schinazi RF, Pedersen NC, North TW.

PLoS One. 2014 Jan 31;9(1):e86997. doi: 10.1371/journal.pone.0086997. eCollection 2014.

5.

Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1262-9. doi: 10.1128/AAC.02012-12. Epub 2012 Dec 21.

6.

Simian immunodeficiency virus macaque models of HIV latency.

Deere JD, Schinazi RF, North TW.

Curr Opin HIV AIDS. 2011 Jan;6(1):57-61. doi: 10.1097/COH.0b013e32834086ce. Review.

PMID:
21242894
7.

Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.

Deere JD, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E, Schinazi RF, Luciw PA, North TW.

PLoS One. 2010 Jul 23;5(7):e11640. doi: 10.1371/journal.pone.0011640.

8.

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.

North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA.

J Virol. 2010 Mar;84(6):2913-22. doi: 10.1128/JVI.02356-09. Epub 2009 Dec 23.

9.

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW.

Retrovirology. 2007 Apr 6;4:25.

10.

Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.

Duong YT, Meadows DC, Srivastava IK, Gervay-Hague J, North TW.

Antimicrob Agents Chemother. 2007 May;51(5):1780-6. Epub 2007 Feb 16.

11.

Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.

Meadows DC, Sanchez T, Neamati N, North TW, Gervay-Hague J.

Bioorg Med Chem. 2007 Jan 15;15(2):1127-37. Epub 2006 Oct 30.

12.

Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors.

Meadows DC, Mathews TB, North TW, Hadd MJ, Kuo CL, Neamati N, Gervay-Hague J.

J Med Chem. 2005 Jul 14;48(14):4526-34.

PMID:
15999991
15.

Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW.

Antimicrob Agents Chemother. 2004 Sep;48(9):3483-90.

16.

Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides.

North TW, Sequar G, Townsend LB, Drach JC, Barry PA.

Antimicrob Agents Chemother. 2004 Jul;48(7):2760-5.

17.

16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression.

Pedersen NC, North TW, Rigg R, Reading C, Higgins J, Leutenegger C, Henderson GL.

Vet Immunol Immunopathol. 2003 Aug 15;94(3-4):133-48.

PMID:
12909410
18.

Susceptibilities of simian immunodeficiency virus to protease inhibitors.

Giuffre AC, Higgins J, Buckheit RW Jr, North TW.

Antimicrob Agents Chemother. 2003 May;47(5):1756-9.

19.

Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.

Murry JP, Higgins J, Matthews TB, Huang VY, Van Rompay KK, Pedersen NC, North TW.

J Virol. 2003 Jan;77(2):1120-30.

20.
21.

Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.

Van Rompay KK, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC, North TW.

J Virol. 2002 Jun;76(12):6083-92.

22.
23.

Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA.

Leutenegger CM, Higgins J, Matthews TB, Tarantal AF, Luciw PA, Pedersen NC, North TW.

AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):243-51.

PMID:
11177407
25.

A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Smith RA, Klarmann GJ, Stray KM, von Schwedler UK, Schinazi RF, Preston BD, North TW.

Antimicrob Agents Chemother. 1999 Aug;43(8):2077-80.

26.

Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1.

Elder JH, Dean GA, Hoover EA, Hoxie JA, Malim MH, Mathes L, Neil JC, North TW, Sparger E, Tompkins MB, Tompkins WA, Yamamoto J, Yuhki N, Pedersen NC, Miller RH.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):797-801. No abstract available.

PMID:
9643379
28.
29.
30.

Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.

Arts EJ, Stetor SR, Li X, Rausch JW, Howard KJ, Ehresmann B, North TW, Wöhrl BM, Goody RS, Wainberg MA, Grice SF.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10063-8.

31.

Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Zhu YQ, Remington KM, North TW.

Antimicrob Agents Chemother. 1996 Sep;40(9):1983-7.

32.

Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus.

Chen H, McBroom DG, Zhu YQ, Gold L, North TW.

Biochemistry. 1996 May 28;35(21):6923-30.

PMID:
8639644
33.

The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.

LaCasse RA, Remington KM, North TW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 May 1;12(1):26-32.

PMID:
8624757
34.

Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Medlin HK, Zhu YQ, Remington KM, Phillips TR, North TW.

Antimicrob Agents Chemother. 1996 Apr;40(4):953-7.

35.

Testing anti-HIV drugs in the FIV model.

North TW, LaCasse RA.

Nat Med. 1995 May;1(5):410-1. No abstract available.

PMID:
7585083
36.

Models of antiviral resistance.

Kimberlin DW, Kern ER, Sidwell RW, North TW, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):415-22. Review. No abstract available.

PMID:
7574543
37.
38.

One of two growth hormone genes in coho salmon is sex-linked.

Forbes SH, Knudsen KL, North TW, Allendorf FW.

Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1628-31.

39.

Expression of reverse transcriptase from feline immunodeficiency virus in Escherichia coli.

North TW, Hansen GL, Zhu Y, Griffin JA, Shih CK.

Antimicrob Agents Chemother. 1994 Feb;38(2):388-91.

40.
41.

Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants.

Barlough JE, North TW, Oxford CL, Remington KM, Dandekar S, Ellis MN, Pedersen NC.

Antiviral Res. 1993 Dec;22(4):259-72.

PMID:
8279815
42.

Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2'-deoxyadenosine-5'-triphosphate.

Cronn RC, Remington KM, Preston BD, North TW.

Biochem Pharmacol. 1992 Oct 6;44(7):1375-81.

PMID:
1384501
43.
44.

Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW.

J Virol. 1991 Jan;65(1):308-12.

45.

Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses.

North TW, Cronn RC, Remington KM, Tandberg RT.

Antimicrob Agents Chemother. 1990 Aug;34(8):1505-7.

46.

Characterization of reverse transcriptase from feline immunodeficiency virus.

North TW, Cronn RC, Remington KM, Tandberg RT, Judd RC.

J Biol Chem. 1990 Mar 25;265(9):5121-8.

47.
48.

DNA synthesis in promastigotes of Leishmania major and L. donovani.

North TW, Wyler DJ.

Mol Biochem Parasitol. 1987 Jan 15;22(2-3):215-21.

PMID:
2437451
49.

Supplemental Content

Loading ...
Support Center